These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36762414)

  • 21. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inpatient Initiation of Sacubitril/Valsartan.
    Chilbert MR; Rogers KC; Ciriello DN; Rovelli R; Woodruff AE
    Ann Pharmacother; 2021 Apr; 55(4):480-495. PubMed ID: 32741197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients.
    Imamura T; Kinugawa K
    Ann Palliat Med; 2022 Sep; 11(9):2856-2861. PubMed ID: 36096739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.
    Vodovar N; Séronde MF; Laribi S; Gayat E; Lassus J; Boukef R; Nouira S; Manivet P; Samuel JL; Logeart D; Ishihara S; Cohen Solal A; Januzzi JL; Richards AM; Launay JM; Mebazaa A;
    Eur Heart J; 2014 Dec; 35(48):3434-41. PubMed ID: 25157115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
    Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
    Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.
    Mapelli M; Mattavelli I; Salvioni E; Bonomi A; Capra N; Palermo P; Banfi C; Paolillo S; Biondi ML; Agostoni P
    Drugs R D; 2023 Dec; 23(4):397-402. PubMed ID: 37702906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
    Sbolli M; deFilippi C
    Curr Cardiol Rep; 2020 Sep; 22(11):150. PubMed ID: 32951154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA
    JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
    Masson S; Latini R; Anand IS; Vago T; Angelici L; Barlera S; Missov ED; Clerico A; Tognoni G; Cohn JN;
    Clin Chem; 2006 Aug; 52(8):1528-38. PubMed ID: 16777915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
    Myhre PL; Claggett BL; Shah AM; Prescott MF; Ward JH; Fang JC; Mitchell GF; Solomon SD; Desai AS
    Eur J Heart Fail; 2022 Jul; 24(7):1200-1208. PubMed ID: 35560696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BNP molecular forms and processing by the cardiac serine protease corin.
    Ichiki T; Huntley BK; Burnett JC
    Adv Clin Chem; 2013; 61():1-31. PubMed ID: 24015598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes.
    Tonne JM; Campbell JM; Cataliotti A; Ohmine S; Thatava T; Sakuma T; Macheret F; Huntley BK; Burnett JC; Ikeda Y
    Clin Chem; 2011 Jun; 57(6):864-73. PubMed ID: 21482747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides.
    Saenger AK; Rodriguez-Fraga O; Ler R; Ordonez-Llanos J; Jaffe AS; Goetze JP; Apple FS
    Clin Chem; 2017 Jan; 63(1):351-358. PubMed ID: 28062628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
    Butt JH; Ibrahim W; Dewan P; Desai AS; Køber L; Prescott MF; Lefkowitz MP; Rouleau JL; Solomon SD; Zile MR; Packer M; Jhund PS; McMurray JJV
    Circ Heart Fail; 2023 Mar; 16(3):e010111. PubMed ID: 36943907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 39. Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure.
    Huntley BK; Sandberg SM; Heublein DM; Sangaralingham SJ; Burnett JC; Ichiki T
    Circ Heart Fail; 2015 Jan; 8(1):89-97. PubMed ID: 25339504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
    Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
    J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.